Welcome to our dedicated page for Ibio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on Ibio stock.
iBio, Inc. (IBIO) is a biotechnology innovator providing end-to-end CDMO services and AI-driven solutions for biotherapeutics development. This page serves as the definitive source for all official company announcements, regulatory filings, and operational updates.
Investors and industry observers will find timely access to earnings reports, strategic partnerships, regulatory milestones, and technology advancements related to iBio's vaccine development and precision antibody platforms. Our curated feed ensures transparent tracking of the company's progress in accelerating biopharmaceutical production from discovery to commercialization.
All content is sourced directly from iBio's corporate communications, maintaining factual accuracy and compliance with financial disclosure standards. Bookmark this page for efficient monitoring of IBIO's developments in artificial intelligence applications for drug discovery, manufacturing expansions, and clinical trial updates.
iBio, Inc. (NYSEA:IBIO) has acquired full ownership of its CDMO subsidiary and U.S. manufacturing rights for its FastPharming System, reducing carrying costs by approximately 67%. The transaction, valued at $28.75 million, was financed through cash and warrants for stock. This move is expected to enhance strategic flexibility and operational growth in Texas, while iBio anticipates sustaining its operations with its current cash position through Q1 2023.
iBio, Inc. (NYSEA:IBIO) urges stockholders to vote “FOR” all proposals in their proxy statement ahead of the December 9, 2021 Annual Meeting. The proposals include amendments to the Company’s Articles of Incorporation requiring majority approval. Stockholders with shares as of October 15, 2021, are eligible to vote. CEO Tom Isett highlights the importance of shareholder participation for strategic growth. A new Q&A page has been created to facilitate communication. Stockholders can access their voting instructions via proxy cards or by contacting Okapi Partners for assistance.
iBio, a developer of biopharmaceuticals, announced its fiscal Q4 and annual results for 2021. Revenues reached $2.4 million, a 50% increase year-over-year, though Q4 revenue dropped to $0.5 million. Key developments include a partnership with RubrYc for an anti-CD25 antibody, expansion into oncology, and progress on the COVID-19 vaccine, IBIO-202. The company's consolidated net loss widened to $23.2 million, influenced by $10.2 million from a legal settlement. iBio's cash position is robust, at $97 million, allowing funding through Q1 2023.
iBio, Inc. (NYSEA:IBIO), a leader in biopharmaceuticals, announced that its Chairman & CEO, Tom Isett, and CSO, Martin Brenner, will engage in a fireside chat at the Cantor Virtual Global Healthcare Conference on September 27, 2021, at 10:00 a.m. ET. This event will focus on the innovative FastPharming Manufacturing System® and the company’s advancements in biopharmaceutical development. The chat will be broadcast live on the company’s website and archived for future access.
iBio, Inc. (NYSEA:IBIO) is set to report its fiscal fourth quarter and full year 2021 financial results on September 27, 2021, before market open. Management will host a webcast and conference call at 8:30 a.m. ET to discuss the results and provide a corporate update. iBio is renowned for its FastPharming Manufacturing System®, focusing on sustainable, plant-based biopharmaceuticals. The company develops proprietary treatments for cancers, fibrotic, and infectious diseases while offering FastPharming Contract Development and Manufacturing Services.
iBio, Inc. (NYSEA:IBIO) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, taking place virtually from September 13-15, 2021. A pre-recorded presentation by iBio will be available on demand for registered attendees and on their website from September 13. iBio specializes in sustainable, plant-based pharmaceuticals through its FastPharming Manufacturing System®, developing treatments for cancer, fibrotic, and infectious diseases, while also providing contract development services.
iBio, Inc. (NYSE:IBIO) has appointed William D. (Chip) Clark to its Board of Directors, bringing over 30 years of biotechnology experience, particularly in immuno-oncology. His prior leadership at Genocea was marked by a pivotal shift to immuno-oncology, and his insights are expected to support the advancement of IBIO-101 and other therapies. The company aims to leverage its FastPharming Manufacturing System to enhance cancer drug development. The press release also highlights ongoing forward-looking statements regarding regulatory approvals and marketplace acceptance.
iBio licenses a novel antibody targeting regulatory T cells through a worldwide exclusive agreement with RubrYc Therapeutics for RTX-003, enhancing its oncology pipeline. The partnership includes options for additional antibodies from RubrYc's AI-based platform. iBio has acquired an equity stake in RubrYc and is committed to further investment. Preclinical data shows RTX-003 effectively depletes Tregs without blocking IL-2 signaling, promising strong anti-tumor responses. iBio plans to advance RTX-003 to clinical studies as IBIO-101, with IND-enabling studies expected by mid-2022.
iBio announced positive results from preclinical studies of its COVID-19 vaccine candidate, IBIO-202, which targets the nucleocapsid protein of SARS-CoV-2. The studies revealed a strong antigen-specific memory T-cell response, suggesting that IBIO-202 may complement existing spike protein-directed vaccines by enhancing durability against emerging variants. The N protein is more conserved, showing 90% amino acid homology, and can induce T-cell proliferation. Ongoing characterization studies aim to further explore the vaccine's potential.
iBio, a biotech innovator, announced the addition of three anti-cancer targets to its pipeline. This follows its recent drug discovery capability expansion via the FastPharming Protein Expression System. iBio has partnered with FairJourney Biologics for antibody optimization, utilizing their novel display technologies. The collaboration aims to enhance the development of differentiated cancer therapeutic antibodies and improve the process of moving from concept to clinical trials. iBio leverages Glycaneering Technologies to optimize antibody-dependent cell-mediated cytotoxicity.
FAQ
What is the current stock price of Ibio (IBIO)?
What is the market cap of Ibio (IBIO)?
